Table 1.

Summary of SSc clinical trials discussed in this review.

Trials analyzed	Improvers	Non-improvers	Reference
Imatinib mesylate	ND, but response signature overlapped with fibroproliferative subset	NA	Chung et al. 2009
Mycophenolate mofetil (MMF)	Inflammatory	Fibroproliferative	Hinchcliff et al. 2013
Abatacept	Inflammatory; patients with high baseline levels of CD28 signaling	Normal-like; patient with low baseline levels of CD28 signaling	Chakravarty et al. 2015
Nilotinib	Intrinsic subset was variable; patients with high baseline levels of TGFBR/PDGFRB signaling	Fibroproliferative; patients with low baseline levels of TGFBR/PDGFRB signaling	Gordon et al. 2015

For each trial, information about improvers and non-improvers in terms of intrinsic subsets and relevant targeted pathways is provided (where applicable). NA – not available, ND – not determined.